You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
特一藥業(002728.SZ):公司藥品磺胺嘧啶片首家通過一致性評價
格隆匯 02-21 18:49

格隆匯 2 月 21日丨特一藥業(002728.SZ)公佈,公司於近日獲得國家藥品監督管理局核準簽發的“磺胺嘧啶片”《藥品補充申請批准通知書》,通知書編號:2021B00293審查,本品通過仿製藥質量和療效一致性評價。公司藥品磺胺嘧啶片為首家通過一致性評價

磺胺嘧啶屬中效磺胺,對非產酶金葡菌、化膿性鏈球菌、肺炎鏈球菌、大腸埃希菌、克雷伯菌屬、沙門菌屬、志賀菌屬等腸桿菌科細菌、淋球菌、腦膜炎球菌、流感嗜血杆菌具有抗菌作用,此外在體外對沙眼衣原體、星形奴卡菌、瘧原蟲和弓形蟲也有抗微生物活性。該藥可以用於敏感細菌及其他敏感病原微生物引起的下列感染:1、敏感腦膜炎球菌所致的流行性腦脊髓膜炎的治療和預防。2、與甲氧苄啶合用可治療對其敏感的流感嗜血桿菌、肺炎鏈球菌和其他鏈球菌所致的中耳炎及皮膚軟組織等感染。3、星形奴卡菌病。4、對氯喹耐藥的惡性瘧疾治療的輔助用藥。5、治療由沙眼衣原體所致的宮頸炎和尿道炎的次選藥物。6、治療由沙眼衣原體所致的新生兒包涵體結膜炎的次選藥物。

根據國家相關政策,通過一致性評價的藥品品種,質量和療效等同原研產品,在醫保支付及醫療機構採購方面將予以適當支持。在國家鼓勵優先採購和使用通過一致性評價的產品的政策背景下,公司藥品磺胺嘧啶片首家通過一致性評價,對公司有積極影響,有利於進一步增強該藥品的技術優勢,提升市場競爭力,擴大市場份額。同時,也為公司後續品種通過仿製藥質量和療效一致性評價提供了重要的經驗借鑑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account